



Market Announcement

5 December 2024

Recce Pharmaceuticals Ltd (ASX: RCE) – Trading Halt

Description

The securities of Recce Pharmaceuticals Ltd ('RCE') will be placed in trading halt at the request of RCE, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 9 December 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

5 December 2024

Barbara Lim
Adviser, Listing Compliance (Perth)
Level 40 Central Park
152 - 158 St Georges Terrace
Perth WA 6000

By email: tradinghaltspert@asx.com.au

Dear Barbara,

Recce Pharmaceuticals Ltd (ASX:RCE) – Trading halt request

Pursuant to ASX Listing Rule 17.1, Recce Pharmaceuticals Ltd (**Company**) requests a trading halt of the Company's securities pending the release of a material announcement relating to a Registrational Phase 3 Diabetic Foot Ulcer Infection Approval (the '**Approval**').

The Company requests that the trading halt be effective immediately and remain in place until the earlier of the commencement of normal trading on Monday, 9 December 2024 or the release of an announcement by the Company in relation to the Approval.

The Company is not aware of any reason why the trading halt should not be granted nor any other information necessary to inform the market about the trading halt.

This announcement has been approved for release by Recce Pharmaceuticals Board.

For further information, please contact:

Maggie Niewidok
Company Secretary
company.secretary@recce.com.au



ASX: RCE, **FSE:** R9Q

Head Office: Level 23, 180 George St, Salesforce Tower, SYDNEY NSW 2000 **T** +61 (02) 9256 2505

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA